MaxCyte, Inc. (MXCT): Price and Financial Metrics

MaxCyte, Inc. (MXCT): $2.26

0.12 (-5.04%)

POWR Rating

Component Grades

Momentum

D

Stability

C

Sentiment

Quality

C

MXCT Price/Volume Stats

Current price $2.26 52-week high $5.26
Prev. close $2.38 52-week low $2.10
Day low $2.24 Volume 708,577
Day high $2.36 Avg. volume 768,193
50-day MA $2.57 Dividend yield N/A
200-day MA $3.60 Market Cap 240.28M

MXCT Stock Price Chart Interactive Chart >


MaxCyte, Inc. (MXCT) Company Bio


MaxCyte, Inc. operates as a cell-based therapies and life sciences company in the United States and internationally. Its transfection systems include MaxCyte STX, a scalable transfection system that uses flow electroporation technology for the engineering of cells for a range of applications; MaxCyte VLX, an instrument for large volume cell-engineering; and MaxCyte GT, a non-viral cell-engineering technology designed for clinical use. The company also provides single use sterile processing assemblies; and proprietary electroporation buffers; and ExPERT brand series of instruments and consumables, as well as insourcing services. In addition, it develops CARMA, a novel and proprietary technology for the development of non-viral, human messenger RNA-based, chimeric antigen receptor or T-cell receptor redirected immune cell therapies. The company licenses and sells its instruments and technology; and sells its products to drug developers and biopharmaceutical companies. It has a clinical and commercial license agreement with Allogene Therapeutics, Inc. The company was founded in 1998 and is headquartered in Gaithersburg, Maryland.


MXCT Latest News Stream


Event/Time News Detail
Loading, please wait...

MXCT Latest Social Stream


Loading social stream, please wait...

View Full MXCT Social Stream

MXCT Price Returns

1-mo -19.86%
3-mo -34.11%
6-mo -38.42%
1-year -49.55%
3-year -50.55%
5-year N/A
YTD -45.67%
2024 -11.49%
2023 -13.92%
2022 -46.42%
2021 N/A
2020 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!